Hims & Hers Health (NYSE: HIMS) reported another blowout quarter recently, but the stock didn't get the type of pop that ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Hims & Hers is revolutionizing telehealth and wellness for millennials and Gen Z with rapid revenue growth and positive net ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Tuesday after the company reported strong third-quarter ...

TD Cowen analyst Jonna Kim raised the firm’s price target on Hims & Hers to $28 from $25 and keeps a Buy rating on the shares. The firm said HIMS has ample opportunities to grow weight loss as a ...

Bearish flow noted in Hims and Hers Health with 30,788 puts trading, or 9x expected. Most active are Dec-24 21 puts and Dec-24 22 puts, with ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.